Research from MIA’s PhD student, Jordan Conway, has shed light on why advanced melanoma that has spread to the liver is particularly resistant to immunotherapy.
The discovery of dramatic genetic changes in melanoma cells as the disease progresses may be key to developing new treatments for melanoma.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.